HealthAnswer before:
Will the US approve a new cell therapy for Duchenne muscular dystrophy?
How the result is determined
Yes if Capricor officially reports FDA marketing approval of deramiocel for Duchenne muscular dystrophy with an action date no later than November 22, 2026 in Washington, DC. A final rejection means No; a delay or no decision requires separate review. Observation: November 23 at 18:00 Moscow time.
Result source